Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (CARL) will report its third quarter 2026 financial results after market close on November 10, 2026.
Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time. The live webcast will be available on the company’s investor website, with a replay archived after the call.
Carlsmed (Nasdaq: CARL) launched its aprevo® Lumbar Bi-lateral Posterior System commercially in the United States at a spine surgery meeting. The launch took place at the North American Spine Society’s 41st Annual Meeting in San Antonio, Texas. It follows a limited market evaluation that began in February 2026, with the first procedure in a human completed on February 10, 2026.
Carlsmed (CARL) granted equity awards to its newly hired Chief Financial Officer and Chief Product and AI Officer as employment inducements.
On September 28, 2026, Chief Financial Officer Richard Heppenstall received options to purchase 180,137 shares and 89,286 time-based restricted stock units (RSUs). On October 1, 2026, Chief Product and AI Officer Anthony Jarc received options to purchase 132,464 shares and 63,735 time-based RSUs. The options' exercise prices equal the shares' fair market value on each respective grant date. The independent-director Compensation Committee approved the awards outside the equity incentive plan under Nasdaq Listing Rule 5635(c)(4).
Carlsmed (Nasdaq: CARL) appointed Tony Jarc as Chief Product and AI Officer, effective immediately, in a newly created executive position. He will lead development and commercialization of the next-generation technology platform, surgical user interfaces and personalized spine surgery procedures.
Jarc joins from Intuitive Surgical, where he most recently served as Vice President, Digital Products and Machine Learning Insights during a tenure exceeding 15 years. His appointment follows Rich Heppenstall’s appointment as CFO and Jeff Bertolini’s promotion to COO. Enhanced CMS reimbursement for all aprevo lumbar fusion procedures took effect October 1, 2026.
Carlsmed (CARL) appointed Richard Heppenstall chief financial officer, succeeding Leo Greenstein, and reaffirmed its fiscal 2026 revenue outlook. Heppenstall takes the role immediately. Greenstein, CFO since 2023, is leaving to pursue other professional interests. Full-year revenue guidance remains $74 million to $78 million, representing 50% growth over 2025 at the range’s midpoint.
CMS reimbursement for the aprevo Lumbar spinal fusion procedure is set to take effect October 1. Carlsmed also expects to launch the aprevo Lumbar Bi-lateral and corra cervical procedures.
Summary not available.
Carlsmed (CARL) has promoted Jeff Bertolini to Chief Operating Officer, effective immediately as of the September 8, 2026 announcement.
Bertolini joined Carlsmed in September 2024 and most recently served as Senior Vice President, Operational Excellence, after previously holding the role of Vice President of Advanced Manufacturing Technologies. Before joining Carlsmed, he held senior operations and technology leadership positions at SI-BONE, NuVasive, and US Surgical.
The company credits Bertolini with driving the deployment of advanced technologies across its digital production process to accelerate scale and capabilities for its AI-enabled personalized spine surgery solutions. He holds an MBA from Rensselaer Polytechnic Institute, a Bachelor of Science in Procurement and Logistics Management from Arizona State University, and has completed executive programs at the Wharton School and MIT Professional Education in Applied Data Science.
Carlsmed (Nasdaq: CARL) reported second quarter 2026 revenue of $18.9 million, up 57% year-over-year from $12.1 million, with gross margin improving to 76.8% from 73.4%. Gross profit rose to $14.5 million while operating expenses increased to $25.6 million, driving a net loss of ($10.5) million versus ($6.8) million a year earlier. Adjusted EBITDA was ($8.6) million compared to ($6.2) million. The company ended June 30, 2026 with $89.3 million in cash, equivalents, restricted cash, short-term investments and marketable securities.
Carlsmed raised its full-year 2026 revenue guidance to $74–$78 million from $72–$77 million, implying over 50% growth at the midpoint versus 2025. Management highlighted over 60% growth in trained surgeon users, aprevo® cervical reaching ~10% of quarterly revenue, and a finalized CMS IPPS rule adding three new MS-DRG codes with favorable reimbursement for inpatient aprevo® lumbar procedures effective October 1, 2026.
Carlsmed (Nasdaq: CARL) announced that the Centers for Medicare & Medicaid Services finalized a favorable reimbursement policy for inpatient aprevo® Lumbar spinal fusion procedures in the FY27 IPPS Final Rule. Effective October 1, 2026, these procedures are reassigned to three new MS-DRGs (523, 524, 525), making all inpatient aprevo® Lumbar fusions eligible for reimbursement under these codes.
Carlsmed (Nasdaq: CARL) will participate in two upcoming virtual investor conferences. Management will attend the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference with one-on-one meetings on Monday, August 10, 2026. Carlsmed will also join the Bank of America SMID Cap Virtual Conference, featuring a fireside chat on Wednesday, August 12, 2026 at 11:00 AM ET, with a live and archived webcast available in the Events & Presentations section of its investor website.